Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Other Financing Activities

Financing cash flows not reported separately.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow shrinks to $0

Q1 FY2026 other financing activities was $0, compared with $1K a year earlier. Trailing-twelve-month other financing activities was -$2K. Over 3 fiscal years it compounded at -87.1% a year.

Context

  • Other financing activities amounted to 2.8% of revenue in FY2025, down 121.8 pp from a year earlier.
  • Other financing activities grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$500.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$1K-98.7% YoY
LTMMar 2026
-$2K-300.0% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-98.7%——
3-year CAGR-87.1%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(1K) USD
Year-over-year change
+98.7%

Other Financing Activities vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -300.0% is the lowest of 9, against a peer median of +52.7%.
  • Other financing activities amounts to 6.5% of revenue for LYEL, versus a peer median of 0.0%.
LYEL Competitors
Other Financing Activities for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CABACabaletta Bio, Inc.LTM Mar 2026$6.05M USD+5.3%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$3.56M USD-43.4%——
EDITEditas Medicine, Inc.LTM Mar 2026$2.89M USD+200.7%—7.5%
AMRNAmarin Corporation plcLTM Mar 2026$2.73M USD+117.1%+27.8%1.3%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$333K USD+338.2%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$2K USD-300.0%-87.1%6.5%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.03K CHF+100.2%—0.0%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD——0.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
GNLXGenelux CorporationLTM Mar 2026$0 USD-100.0%—0.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding LYEL) —+52.7%+27.8%0.0%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.